Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with Waldenström's Macroglobulinaemia (WM). Update February 2022

Wolf, S. (2021): Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with Waldenström's Macroglobulinaemia (WM). Update February 2022. Oncology Fact Sheet Nr. 60.

[thumbnail of Oncology Fact Sheet Nr.60_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
771kB

Item Type:	Oncology Fact Sheet
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WH Hemic and lymphatic systems
Language:	English
Series Name:	Oncology Fact Sheet Nr. 60
Deposited on:	15 Oct 2021 15:12
Last Modified:	09 Feb 2022 18:06

Repository Staff Only: item control page